Breast Cancer

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA
FDA
FDA Approves New Indications for 2 Epilepsy Treatments
09/15/2017
The FDA has approved new indication for 2 previously-approved treatment option for partial-onset seizures.
09/15/2017
FDA
FDA
FDA Approves New Indications for 2 Epilepsy Treatments
09/15/2017
The FDA has approved new indication for 2 previously-approved treatment option for partial-onset seizures.
09/15/2017
FDA
FDA
FDA Approves New Indications for 2 Epilepsy Treatments
09/15/2017
The FDA has approved new indication for 2 previously-approved treatment option for partial-onset seizures.
09/15/2017
FDA
FDA
FDA: First Treatment Option for Pediatric PAH
09/07/2017
The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
09/07/2017
FDA
FDA
FDA: First Treatment Option for Pediatric PAH
09/07/2017
The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
09/07/2017
FDA
FDA
FDA: First Treatment Option for Pediatric PAH
09/07/2017
The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.
09/07/2017
Drug Therapy
Drug Therapy
FDA Approves New Drug for AML Subtype
09/01/2017
The US Food and Drug Administration has approved a new treatment option for adult and pediatric patients with CD33-positive acute myeloid leukemia.
09/01/2017
Drug Therapy
Drug Therapy
FDA Approves New Treatment for Tardive Dyskinesia
09/01/2017
After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.
09/01/2017
Drug Therapy
Drug Therapy
FDA Approves New Treatment for Tardive Dyskinesia
09/01/2017
After clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved a new option for adult patients with tardive dyskinesia.
09/01/2017
FDA
FDA
FDA Approves First Gene Therapy in the US
08/30/2017
The FDA has approved the first CAR T-cell therapy available in the United States for the treatment of certain pediatric patients.
08/30/2017